Pharsight

Drugs that contain Plecanatide

1. Trulance patents expiration

TRULANCE's oppositions filed in EPO
TRULANCE IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7799897 SALIX Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis
Jun, 2022

(1 year, 11 months ago)

US7041786 SALIX Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis
Jan, 2028

(3 years from now)

US10011637 SALIX Ultra-pure agonists of guanylate cyclase C, method of making and using same
Jun, 2034

(10 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8637451 SALIX Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis
Mar, 2022

(2 years ago)

US9925231 SALIX Formulations of guanylate cyclase C agonists and methods of use
Sep, 2031

(7 years from now)

US9610321 SALIX Formulations of guanylate cyclase C agonists and methods of use
Sep, 2031

(7 years from now)

US9919024 SALIX Formulations of guanylate cyclase C agonists and methods of use
Sep, 2031

(7 years from now)

US11319346 SALIX Ultra-pure agonists of guanylate cyclase C, method of making and using same
Mar, 2032

(7 years from now)

US9616097 SALIX Formulations of guanylate cyclase C agonists and methods of use
Aug, 2032

(8 years from now)

US11142549 SALIX Ultra-pure agonists of guanylate cyclase C, method of making and using same
Jun, 2034

(10 years from now)

US11834521 SALIX Ultra-pure agonists of guanylate cyclase C, method of making and using same
Jun, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 19, 2022
New Indication(I-764) Jan 24, 2021

NCE-1 date: 19 January, 2021

Market Authorisation Date: 19 January, 2017

Treatment: Elevation of intracellular cgmp resulting in increased intestinal fluid and accelerated transit; Irritable bowel syndrome with constipation; Chronic idiopathic constipation

Dosage: TABLET;ORAL

How can I launch a generic of TRULANCE before it's drug patent expiration?
More Information on Dosage

TRULANCE family patents

Family Patents